AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20663491 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 113
Study 20663491 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment conditions
Number of subjects: 113
Study 17175561 — intervention group
Group type: EXPERIMENTAL
Intervention: CareFile booklet (intervention group)
Number of subjects: 100
Study 17175561 — intervention group
Group type: COMPARATOR
Intervention: Usual stroke information leaflets (control group)
Number of subjects: 100
Study 15785218 — intervention group
Group type: EXPERIMENTAL
Intervention: GSM mobile telephone short-message service (SMS)
Number of subjects: 16
Study 15785218 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 12360156 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) therapy
Number of subjects: 0
Study 12360156 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) therapy with GP IIb/IIIa receptor antagonists
Number of subjects: 0
Study 9469979 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosensitizer tablets Nimorazol given 1 1/2 hours before radiation, six fractions weekly for patients with squamous cell cancer in the supraglottic region, pharynx and oral cavity.
Number of subjects: 1800
Study 9469979 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (specific details not provided).
Number of subjects: 1800
Study 7658328 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO
Number of subjects: 0
Study 7658328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2665110 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Self‐management Course (ASMC) + bi‐monthly arthritis newsletter
Number of subjects: 589
Study 2665110 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Self‐management Course (ASMC) + 6-week Arthritis Reinforcement Course (ARC)
Number of subjects: 589
Study 2665110 — intervention group
Group type: COMPARATOR
Intervention: Arthritis Self‐management Course (ASMC) + no reinforcement
Number of subjects: 589
Study 141020 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian loci needling (MLN)
Number of subjects: 40
Study 141020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tender area needling (TAN)
Number of subjects: 40
Study 141020 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy after subarachnoid injection of 0.25% procaine
Number of subjects: 40
Study 141020 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy after 1% procaine sensory and motor blockade
Number of subjects: 40
Study 141020 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential spinal block (DSB)
Number of subjects: 40
Study 30669914 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway clearance techniques (ACTs)
Number of subjects: 7
Study 30958058 — intervention group
Group type: EXPERIMENTAL
Intervention: External Counterpulsation (ECP)
Number of subjects: 7
Study 30958058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 27264267 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus gemcitabine (DG) - docetaxel 30 mg/m2 plus gemcitabine 900 mg/m2 i.v. on days 1 and 8, every 3 weeks
Number of subjects: 106
Study 27264267 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (G) - gemcitabine 1200 mg/m2 i.v. on days 1 and 8, every 3 weeks
Number of subjects: 106
Study 27264267 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental Activities of Daily Living (IADL) score < 7
Number of subjects: 106
Study 27264267 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental Activities of Daily Living (IADL) score ≥ 7
Number of subjects: 106
Study 26002805 — intervention group
Group type: COMPARATOR
Intervention: Cupid2 female condom
Number of subjects: 300
Study 26002805 — intervention group
Group type: COMPARATOR
Intervention: Velvet female condom
Number of subjects: 300
Study 26002805 — intervention group
Group type: EXPERIMENTAL
Intervention: FC2 female condom
Number of subjects: 300
Study 26002805 — intervention group
Group type: COMPARATOR
Intervention: All female condoms
Number of subjects: 300
Study 24483110 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianbu Tongluo Xunzheng Liquid (JTXL), fumigated for 30 min once daily for 10 times (3 courses total)
Number of subjects: 105
Study 24483110 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of JTXL fumigation and Sodium Hyaluronate Injection (SHI), 3 mL each time, once per 6 days for 5 times
Number of subjects: 105
Study 24483110 — intervention group
Group type: COMPARATOR
Intervention: Sodium Hyaluronate Injection (SHI), 3 mL each time, once per 6 days for 5 times
Number of subjects: 105
Study 21222114 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-obturator tape (TOT; Monarc, American Medical Systems)
Number of subjects: 114
Study 21222114 — intervention group
Group type: COMPARATOR
Intervention: Trans-vaginal tape (TVT; Gynecare)
Number of subjects: 114
Study 21222114 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TOT and TVT
Number of subjects: 114
Study 19839536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomisation in interventional studies
Number of subjects: 0
Study 19839536 — intervention group
Group type: COMPARATOR
Intervention: Cluster randomisation
Number of subjects: 0
Study 17853748 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (Jiaji EA plus laser needle-knife)
Number of subjects: 120
Study 17853748 — intervention group
Group type: COMPARATOR
Intervention: Laser needle-knife group
Number of subjects: 120
Study 17853748 — intervention group
Group type: COMPARATOR
Intervention: Jiaji EA group
Number of subjects: 120
Study 15120821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing
Number of subjects: 2010
Study 15120821 — intervention group
Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 2010
Study 15120821 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall stroke rate
Number of subjects: 2010
Study 15120821 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical characteristics (prior stroke, race, hypertension, etc.)
Number of subjects: 2010
Study 15120821 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation after implantation
Number of subjects: 2010
Study 11281047 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms.kg‐1 rocuronium
Number of subjects: 60
Study 11281047 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms.kg‐1 rocuronium
Number of subjects: 60
Study 11281047 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms.kg‐1 rocuronium
Number of subjects: 60
Study 11281047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9159735 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 30
Study 9159735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8267111 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosialoganglioside (GM1) 100 mg/day i.m. for 6 weeks
Number of subjects: 12
Study 8267111 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 12
Study 3115131 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg b.w. flecainide
Number of subjects: 20
Study 3115131 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 20
Study 31970383 — intervention group
Group type: COMPARATOR
Intervention: High walking ability group (n=60)
Number of subjects: 120
Study 31970383 — intervention group
Group type: EXPERIMENTAL
Intervention: Low walking ability group (n=60)
Number of subjects: 120
Study 29980235 — intervention group
Group type: EXPERIMENTAL
Intervention: KEIGAAF intervention
Number of subjects: 11
Study 29980235 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 11
Study 27056702 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) after RME (n=10)
Number of subjects: 14
Study 27056702 — intervention group
Group type: COMPARATOR
Intervention: Control group (RME alone, n=4)
Number of subjects: 14
Study 25420434 — intervention group
Group type: EXPERIMENTAL
Intervention: VIA
Number of subjects: 259
Study 25420434 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 259
Study 23616511 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (9 months of weekly play sessions at home)
Number of subjects: 434
Study 23616511 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment (30 mg daily for 6 months)
Number of subjects: 434
Study 23616511 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial stimulation
Number of subjects: 434
Study 21039349 — intervention group
Group type: EXPERIMENTAL
Intervention: Perisciatic infusion of ropivacaine 2 mg/ml at a rate of 5 ml/h
Number of subjects: 40
Study 21039349 — intervention group
Group type: EXPERIMENTAL
Intervention: Perisciatic infusion of ropivacaine 2 mg/ml at a rate of 8 ml/h
Number of subjects: 40
Study 18498923 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0
Study 18498923 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study 16617103 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 (5.0 log(10) PFU)
Number of subjects: 75
Study 16617103 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 (3.0 log(10) PFU)
Number of subjects: 75
Study 16617103 — intervention group
Group type: EXPERIMENTAL
Intervention: YF‐VAX
Number of subjects: 75
Study 16617103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 14635973 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine
Number of subjects: 50
Study 14635973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10642705 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversion carotid endarterectomy (CEA)
Number of subjects: 1353
Study 10642705 — intervention group
Group type: COMPARATOR
Intervention: Standard carotid endarterectomy (CEA)
Number of subjects: 1353
Study 9048325 — intervention group
Group type: EXPERIMENTAL
Intervention: Goniometric measurement by experienced testers (>=10 years experience)
Number of subjects: 10
Study 9048325 — intervention group
Group type: EXPERIMENTAL
Intervention: Goniometric measurement by inexperienced testers (physical therapy students)
Number of subjects: 10
Study 9048325 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimation by experienced testers (>=10 years experience)
Number of subjects: 10
Study 9048325 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimation by inexperienced testers (physical therapy students)
Number of subjects: 10
Study 9048325 — intervention group
Group type: EXPERIMENTAL
Intervention: Goniometric measurement (intertester reliability)
Number of subjects: 10
Study 9048325 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimation (intertester reliability)
Number of subjects: 10
Study 8393273 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose intensity regimens
Number of subjects: 122
Study 8393273 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and vincristine (control group)
Number of subjects: 122
Study 3554461 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin + Gentamycin (C + G)
Number of subjects: 45
Study 3554461 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole + Gentamycin (M + G)
Number of subjects: 45
Study 30189232 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought record condition
Number of subjects: 100
Study 30189232 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 100
Study 26204351 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily foetal movement counting from 28 weeks' gestation (n = 100)
Number of subjects: 208
Study 26204351 — intervention group
Group type: COMPARATOR
Intervention: Standard Iranian antenatal care (n = 108)
Number of subjects: 208
Study 23937186 — intervention group
Group type: EXPERIMENTAL
Intervention: Wise feedback (treatment condition)
Number of subjects: 0
Study 23937186 — intervention group
Group type: EXPERIMENTAL
Intervention: Attributional retraining (Study 3)
Number of subjects: 0
Study 23937186 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 21716318 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous renal angioplasty and stenting (PTRAS)
Number of subjects: 0
Study 21716318 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 0
Study 21992833 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 100
Study 21992833 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management
Number of subjects: 100
Study 21992833 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) and Conventional medical management
Number of subjects: 100
Study 18703471 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4570
Study 18703471 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 4570
Study 15615822 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ramipril at 5 mg/d and valsartan at 80 mg/d with increased furosemide dosage
Number of subjects: 18
Study 15615822 — intervention group
Group type: COMPARATOR
Intervention: Valsartan at 160 mg/d
Number of subjects: 18
Study 15615822 — intervention group
Group type: COMPARATOR
Intervention: Combined ramipril at 5 mg/d and valsartan at 80 mg/d
Number of subjects: 18
Study 15615822 — intervention group
Group type: COMPARATOR
Intervention: Ramipril at 10 mg/d
Number of subjects: 18
Study 12911138 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental workload bicycle exercise in HSP patients
Number of subjects: 10
Study 12911138 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 10
Study 9605723 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 494
Study 9605723 — intervention group
Group type: COMPARATOR
Intervention: Withholding treatment (no AEDs)
Number of subjects: 494
Study 9605723 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent treatment regimens after 3 failures
Number of subjects: 494
Study 9605723 — intervention group
Group type: EXPERIMENTAL
Intervention: AEDs in children with longest remission < 6 months
Number of subjects: 494
Study 9605723 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcome of epilepsy treatment
Number of subjects: 494
Study 7798008 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral soft tissue radiographs interpretation
Number of subjects: 60
Study 2660559 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g sucralfate daily
Number of subjects: 19
Study 2660559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30132821 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg with glycopyrrolate 450 μg (first dose)
Number of subjects: 21
Study 30132821 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg with glycopyrrolate (second dose)
Number of subjects: 21
Study 30132821 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg with glycopyrrolate (first dose)
Number of subjects: 21
Study 30132821 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline 0.9%)
Number of subjects: 21
Study 30132821 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg with glycopyrrolate (first and second doses)
Number of subjects: 21
Study 28251295 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily pin care (group A)
Number of subjects: 135
Study 28251295 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 2 days pin care (group B)
Number of subjects: 135
Study 28251295 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly pin care (group C)
Number of subjects: 135
Study 28251295 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 135
Study 26690350 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMNC transplantation
Number of subjects: 26
Study 26690350 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 26
Study 22815282 — intervention group
Group type: EXPERIMENTAL
Intervention: 6° full‐length medially wedged foot orthoses
Number of subjects: 20
Study 21165642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient ingestion (24 g whey, 4.8 g leucine, 50 g maltodextrin)
Number of subjects: 8
Study 21165642 — intervention group
Group type: COMPARATOR
Intervention: Non-caloric placebo ingestion
Number of subjects: 8
Study 19705947 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable Hawley retainer
Number of subjects: 70
Study 19705947 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded retainers
Number of subjects: 70
Study 19705947 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 17197088 — intervention group
Group type: COMPARATOR
Intervention: Pain-induced changes in plasma beta-endorphin (BE) following acute pain tasks (finger pressure, ischemic, and thermal)
Number of subjects: 27
Study 17197088 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger-out
Number of subjects: 27
Study 17197088 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger-in
Number of subjects: 27
Study 14575732 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring of parents with bipolar disorder (BD)
Number of subjects: 20
Study 14575732 — intervention group
Group type: COMPARATOR
Intervention: Offspring of parents with no mental disorder (NMD)
Number of subjects: 20
Study 11544839 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of progestins and anticoagulants (500 mg, i.v., for 10 days for AH; 20 days for moderately- and poorly-differentiated cell CAC)
Number of subjects: 120
Study 11544839 — intervention group
Group type: COMPARATOR
Intervention: Preoperative progestin therapy without anticoagulants
Number of subjects: 120
Study 9773139 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (2 micrograms.kg‐1.min‐1)
Number of subjects: 30
Study 9773139 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study 8162733 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination (SDD)
Number of subjects: 2210
Study 3006980 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg b.w. propranolol
Number of subjects: 10
Study 3006980 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 29057618 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab 0.25 mg/kg
Number of subjects: 135
Study 29057618 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab 1 mg/kg
Number of subjects: 135
Study 29057618 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab 3 mg/kg
Number of subjects: 135
Study 29057618 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab 6 mg/kg
Number of subjects: 135
Study 29057618 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab 6 mg/kg (all three doses)
Number of subjects: 135
Study 26669255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame oil Shirodhara (SOS)
Number of subjects: 20
Study 26669255 — intervention group
Group type: COMPARATOR
Intervention: Warm water Shirodhara (WWS)
Number of subjects: 20
Study 24810827 — intervention group
Group type: EXPERIMENTAL
Intervention: Abductor shuck (AS) method
Number of subjects: 81
Study 24810827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranosseous pins with calibrated caliper (TP) method
Number of subjects: 81
Study 24810827 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella electrocardiogram (EKG) leads (PL) method
Number of subjects: 81
Study 21645982 — intervention group
Group type: EXPERIMENTAL
Intervention: CT enterography (CTE)
Number of subjects: 26
Study 21645982 — intervention group
Group type: EXPERIMENTAL
Intervention: MR enterography (MRE)
Number of subjects: 26
Study 21645982 — intervention group
Group type: COMPARATOR
Intervention: CTE and MRE
Number of subjects: 26
Study 20207860 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 98
Study 20207860 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 98
Study 20207860 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 98
Study 20207860 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 98
Study 20207860 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 18314215 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg UDCA
Number of subjects: 31
Study 18314215 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg UDCA
Number of subjects: 31
Study 18314215 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg UDCA
Number of subjects: 31
Study 18314215 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of UDCA
Number of subjects: 31
Study 17267790 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine plus CBT
Number of subjects: 172
Study 17267790 — intervention group
Group type: COMPARATOR
Intervention: Imipramine alone
Number of subjects: 172
Study 17267790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 15593038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialysis (Fresenius F60) for 6 months
Number of subjects: 48
Study 15593038 — intervention group
Group type: COMPARATOR
Intervention: Low-flux dialysis (Fresenius F6 HPS) for 6 months
Number of subjects: 48
Study 10657417 — intervention group
Group type: EXPERIMENTAL
Intervention: Midlife aortic atherosclerosis
Number of subjects: 807
Study 10657417 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of midlife aortic atherosclerosis
Number of subjects: 807
Study 10657417 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-life aortic atherosclerosis
Number of subjects: 807
Study 9069479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lewy body dementia
Number of subjects: 78
Study 9069479 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease
Number of subjects: 78
Study 9069479 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease
Number of subjects: 78
Study 9069479 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 78
Study 8410645 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental oral intervention (taste, smell, and oral tactile stimulation)
Number of subjects: 14